First Time Loading...
N

Nichi-Iko Pharmaceutical Co Ltd
TSE:4541

Watchlist Manager
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Watchlist
Price: 0.0001 JPY
Updated: May 17, 2024

Balance Sheet

Balance Sheet Decomposition
Nichi-Iko Pharmaceutical Co Ltd

Current Assets 177.1B
Cash & Short-Term Investments 13.3B
Receivables 70.3B
Other Current Assets 93.4B
Non-Current Assets 69.4B
Long-Term Investments 11.1B
PP&E 35.9B
Intangibles 22.2B
Other Non-Current Assets 238m
Current Liabilities 182.6B
Accounts Payable 40.7B
Other Current Liabilities 141.9B
Non-Current Liabilities 99.7B
Long-Term Debt 71.8B
Other Non-Current Liabilities 27.9B

Balance Sheet
Nichi-Iko Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: JPY
Mar-2013 Mar-2014 Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022
Assets
Cash & Cash Equivalents
5 309
21 695
14 032
28 179
12 457
18 529
42 093
42 944
29 142
15 305
Cash Equivalents
5 309
21 695
14 032
28 179
12 457
18 529
42 093
42 944
29 142
15 305
Short-Term Investments
0
1
0
0
366
974
447
425
3 715
425
Total Receivables
26 312
27 794
21 162
24 405
31 703
28 986
28 526
38 521
36 514
34 521
Accounts Receivables
26 312
27 794
21 162
24 405
29 311
27 219
26 573
36 045
33 762
32 731
Other Receivables
0
0
0
0
2 392
1 767
1 953
2 476
2 752
1 790
Inventory
28 131
32 648
42 429
45 340
67 962
74 321
66 783
78 127
96 110
95 745
Other Current Assets
2 611
1 434
2 175
3 700
3 070
5 468
4 873
4 691
9 621
9 395
Total Current Assets
62 363
83 572
79 798
101 624
115 558
128 278
142 722
164 708
175 102
155 391
PP&E Net
30 412
29 750
34 107
38 786
47 417
54 045
55 710
59 201
68 943
39 289
PP&E Gross
0
0
34 107
0
47 417
54 045
55 710
59 201
68 943
39 289
Accumulated Depreciation
0
0
0
0
35 927
39 556
44 587
49 932
55 727
82 965
Intangible Assets
2 857
2 276
3 575
5 845
50 131
45 735
46 721
56 607
56 957
39 609
Goodwill
1 514
1 287
1 077
634
40 486
38 536
42 892
44 322
45 661
18 479
Note Receivable
735
1 932
0
0
0
0
0
0
0
0
Long-Term Investments
4 203
8 568
13 602
8 700
12 426
10 342
18 717
9 991
13 837
7 533
Other Long-Term Assets
837
1 745
1 298
920
2 882
1 428
76
1 990
3 072
258
Other Assets
1 514
1 287
1 077
634
40 486
38 536
42 892
44 322
45 661
18 479
Total Assets
102 921
N/A
129 130
+25%
139 834
+8%
161 128
+15%
268 900
+67%
278 364
+4%
306 838
+10%
336 819
+10%
363 572
+8%
260 559
-28%
Liabilities
Accounts Payable
22 298
22 935
32 755
30 193
47 598
50 686
44 172
61 750
65 359
48 123
Accrued Liabilities
1 171
1 031
0
1 797
0
0
0
0
0
0
Short-Term Debt
4 070
11 856
2 750
14 720
29 116
28 540
29 174
37 613
53 287
60 881
Current Portion of Long-Term Debt
3 769
4 478
4 902
4 723
8 080
6 959
8 261
9 134
9 826
24 648
Other Current Liabilities
7 574
6 421
9 690
12 829
8 569
11 209
10 230
14 193
15 102
13 819
Total Current Liabilities
38 883
46 721
51 618
64 262
93 363
97 394
91 837
122 690
143 574
147 471
Long-Term Debt
11 705
12 591
9 332
10 464
78 674
85 625
90 739
87 045
86 021
77 102
Deferred Income Tax
267
268
925
331
5 226
2 823
3 329
4 521
14 711
10 160
Minority Interest
0
0
0
0
0
0
0
1 343
1 268
379
Other Liabilities
3 256
3 355
3 472
3 474
8 466
4 980
4 610
5 393
6 831
12 053
Total Liabilities
54 111
N/A
62 935
+16%
65 347
+4%
78 531
+20%
185 729
+137%
190 822
+3%
190 515
0%
220 992
+16%
252 405
+14%
247 165
-2%
Equity
Common Stock
13 558
19 976
19 976
19 976
19 976
19 976
23 360
23 360
23 360
25 975
Retained Earnings
24 471
28 140
33 343
42 849
45 050
51 912
55 016
57 365
50 822
55 657
Additional Paid In Capital
12 274
18 678
18 684
18 796
18 845
18 827
21 896
21 896
21 896
24 511
Unrealized Security Profit/Loss
411
458
0
0
0
0
0
0
0
0
Treasury Stock
1 904
1 753
1 543
0
9 401
9 046
2 893
2 562
2 267
2 124
Other Equity
0
696
897
771
8 701
5 873
18 944
15 768
17 356
20 689
Total Equity
48 810
N/A
66 195
+36%
74 487
+13%
82 597
+11%
83 171
+1%
87 542
+5%
116 323
+33%
115 827
0%
111 167
-4%
13 394
-88%
Total Liabilities & Equity
102 921
N/A
129 130
+25%
139 834
+8%
161 128
+15%
268 900
+67%
278 364
+4%
306 838
+10%
336 819
+10%
363 572
+8%
260 559
-28%
Shares Outstanding
Common Shares Outstanding
51
60
60
60
56
56
64
64
64
70

See Also

Discover More